EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

Alexis B Cortot iD, Romain Dubois iD, Valérie Grégoire iD, Jean-Baptiste Gibier iD, Julien Labreuche iD, Virginie Deprez iD, Déborah Dubrulle iD, Thomas Chretien iD, Eric Wasielewski iD, Hélène Behal iD, Dai Feng iD, Amber Lind iD und 3 weitere

Histopathology · 2026-09 · 89 (3) · 456-466

DOI: 10.1111/his.70168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 09.06.2026. Verfasst von Alexis B Cortot und 14 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The c‐Met signalling pathway is dysregulated in non‐small cell lung cancer (NSCLC), with c‐Met protein overexpression emerging as a potentially actionable biomarker given the development of c‐Met‐targeted antibody‐drug conjugates. This retrospective study assessed the consistency of c‐Met protein overexpression over time in patients with non‐squamous NSCLC and two or more longitudinal biopsy samples (one before treatment, one post‐treatment). Methods and results Samples from 160 patients were analysed for c‐Met protein expression. The concordance rate for c‐Met protein overexpression between samples was 81.3%, indicating most patients had consistent expression status. Patients with an EGFR mutation had a lower concordance rate (65.8%). Fourteen patients with high discordance (negative to positive) between sampling time points showed a high frequency of oncogenic driver alterations, hence often received targeted therapy before the second sample and had high percentages of cells at 2+ intensity in c‐Met immunohistochemistry before treatment.

Conclusions

These results indicate c‐Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c‐Met status. As targeted therapies may elevate c‐Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c‐Met negative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins c-metLung NeoplasmsBiomarkers, TumorHumansFemaleMaleAgedRetrospective StudiesMiddle AgedImmunohistochemistryAged, 80 and overMutationAdult

Stichwörter der Autor:innen

EGFR mutationNSCLCc‐Met protein overexpressionimmunohistochemistrystatus consistency

Substanzen

Proto-Oncogene Proteins c-metBiomarkers, TumorMET protein, human

Autor:innen und Institutionen

  • CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille, Lille, France.
  • Institute of Pathology, CHU Lille, Lille, France.
  • Department of Biostatistics, CHU Lille, Lille, France.
  • Department of Thoracic Oncology, CHU Lille, Lille, France.
  • AbbVie Inc, North Chicago, Illinois, USA.

ORCID-Profile: Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean-Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut-Millot, Carlos Hader

Förderung

  • AbbVie

Zitieren

APA

Cortot, A. B., Dubois, R., Grégoire, V., Gibier, J. B., Labreuche, J., Deprez, V., Dubrulle, D., Chretien, T., Wasielewski, E., Behal, H., Feng, D., Lind, A., Ansell, P., Thiébaut-Millot, R., & Hader, C. (2026). Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer. Histopathology, 89(3), 456-466. https://doi.org/10.1111/his.70168

Vancouver

Cortot AB, Dubois R, Grégoire V, Gibier JB, Labreuche J, Deprez V, et al. Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer. Histopathology. 2026;89(3):456-466. doi:10.1111/his.70168

BibTeX
@article{Cortot2026,
  author = {Cortot, Alexis B and Dubois, Romain and Grégoire, Valérie and Gibier, Jean-Baptiste and Labreuche, Julien and Deprez, Virginie and Dubrulle, Déborah and Chretien, Thomas and Wasielewski, Eric and Behal, Hélène and Feng, Dai and Lind, Amber and Ansell, Peter and Thiébaut-Millot, Raphaële and Hader, Carlos},
  title = {Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer},
  journal = {Histopathology},
  year = {2026},
  volume = {89},
  number = {3},
  pages = {456--466},
  doi = {10.1111/his.70168}
}
Kostenlos starten →